HDACs as an emerging target in endocrine tumors: a comprehensive review.
Eckhard KlieserBettina NeumayerPietro Di FazioChristian MayrDaniel NeureiterTobias KiesslichPublished in: Expert review of endocrinology & metabolism (2023)
Based on positive pre-clinical results, the research on HDAC (inhibition) in the various endocrine tumors should be intensified - yet, it needs to be considered that i) HDACs' oncogenic actions might constitute only a part of epigenetic mechanisms driving cancer, ii) individual HDAC has different roles in different endocrine tumor entities, iii) inhibition of HDACs might be especially attractive in combination with conventional or other targeted therapies, and iv) new HDAC-inhibiting drugs with improved specificity or functionally modified HDACi might further improve their efficacy.